Biomoneta earns US-FDA Class II clearance for medical air cleaners

December 2, 2025

, By The Economic Times

Biomoneta earns US-FDA Class II clearance for medical air cleaners

Share via:

BENGALURU: ref=”dofollow” data-ga-onclick=”Inarticle articleshow link click#SME#href” href=”https://economictimes.indiatimes.com/topic/biomoneta-research-private-limited” target=”_blank”>Biomoneta Research Private Limited, a Bengaluru-based healthtech company, announces it has received US Food and Drug Administration (FDA) 510(k) Class II clearance for the Biomoneta® Avata Rx Medical Recirculating Air Cleaner. The clearance enables Biomoneta to enter the US and healthcare market with its globally patented ref=”dofollow” data-ga-onclick=”Inarticle articleshow link click#SME#href” href=”https://economictimes.indiatimes.com/topic/zebox-technology” target=”_blank”>ZeBox technology.

The Avata Rx system is built on Biomoneta’s proprietary ZeBox platform, which represents a fundamentally different approach to air decontamination compared to conventional systems. Instead of relying…

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Previous News

Sanchar Saathi, Explained: The DoT order, the privacy debate, and what changes for you

Next News

Apple to resist DOT order to preload state-run Sanchar Saathi app as political outcry builds

The Economic Times

Popular

More Like this

Biomoneta earns US-FDA Class II clearance for medical air cleaners

December 2, 2025

, Published By The Economic Times

Biomoneta earns US-FDA Class II clearance for medical air cleaners

BENGALURU: ref=”dofollow” data-ga-onclick=”Inarticle articleshow link click#SME#href” href=”https://economictimes.indiatimes.com/topic/biomoneta-research-private-limited” target=”_blank”>Biomoneta Research Private Limited, a Bengaluru-based healthtech company, announces it has received US Food and Drug Administration (FDA) 510(k) Class II clearance for the Biomoneta® Avata Rx Medical Recirculating Air Cleaner. The clearance enables Biomoneta to enter the US and healthcare market with its globally patented ref=”dofollow” data-ga-onclick=”Inarticle articleshow link click#SME#href” href=”https://economictimes.indiatimes.com/topic/zebox-technology” target=”_blank”>ZeBox technology.

The Avata Rx system is built on Biomoneta’s proprietary ZeBox platform, which represents a fundamentally different approach to air decontamination compared to conventional systems. Instead of relying…

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

Previous News

Sanchar Saathi, Explained: The DoT order, the privacy debate, and what changes for you

Next News

Apple to resist DOT order to preload state-run Sanchar Saathi app as political outcry builds

The Economic Times

More like this

Popular

Block title